Extracorporeal Removal of mTOR and DAP-1 Proteins for Cockayne Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Cockayne Syndrome, such as Prodarsan, are inadequate in addressing the progressive impairment and accelerated aging phenotypes caused by DNA repair and checkpoint regulation deficits, particularly in CS-B deficient cells, which exhibit increased oxidative stress and impaired autophagy.
Innovation Solution
An extracorporeal method involving the removal of mTOR and/or DAP-1 proteins from a patient's blood or cerebral spinal fluid using immunoprecipitation with specific antibodies, followed by dialysis or molecular filtration, to reverse the bioenergetic phenotype and alleviate the symptoms of Cockayne Syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Prodarsan is used to reduce DNA damage accumulation, then DNA repair is improved, but the treatment is inadequate for addressing progressive impairment and accelerated aging phenotypes
Solution Approach 1:
The patent extracts and removes mTOR and DAP-1 proteins from the patient's body through extracorporeal treatment. This directly addresses the root cause of the disease by eliminating the problematic proteins that inhibit autophagy and cause cellular damage, rather than just treating symptoms or using inadequate drug therapy.
Solution Approach 2:
The patent changes the concentration parameter of mTOR and DAP-1 proteins in the body by removing them through immunoprecipitation and filtration. This parameter change restores normal autophagy function and cellular metabolism, addressing multiple aspects of the disease simultaneously including progressive impairment and accelerated aging phenotypes.
2Reliability
If mTOR and DAP-1 proteins are present in the body, then cellular processes are regulated, but progressive impairment and accelerated aging occur due to inhibited autophagy
Solution Approach 1:
The patent converts the harmful presence of mTOR and DAP-1 proteins into a benefit by using antibodies specific to these proteins to selectively remove them. The same proteins that cause disease when present in excess become the target of a precise removal system, transforming the problem into a solution through immunoprecipitation technology.
Solution Approach 2:
The patent changes the concentration parameter of mTOR and DAP-1 proteins from pathological levels to therapeutic levels by removing them through extracorporeal treatment. This parameter change restores normal autophagy function and cellular metabolism, addressing multiple aspects of the disease simultaneously including progressive impairment and accelerated aging phenotypes.
3Reliability
If CS-B deficient cells are present, then DNA repair function is impaired, but oxidative stress and mitochondrial dysfunction increase
Solution Approach 1:
The patent extracts and removes mTOR and DAP-1 proteins from the patient's body through extracorporeal treatment. This directly addresses the root cause of the disease by eliminating the problematic proteins that inhibit autophagy and cause cellular damage, rather than just treating symptoms or using inadequate drug therapy.
Solution Approach 2:
The patent changes the concentration parameter of mTOR and DAP-1 proteins in the body by removing them through immunoprecipitation and filtration. This parameter change restores normal autophagy function and cellular metabolism, addressing multiple aspects of the disease simultaneously including progressive impairment and accelerated aging phenotypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces the levels of mTOR and DAP-1 proteins in the bodily fluids, potentially slowing and reversing the disease processes by enhancing autophagy and improving cellular repair mechanisms, thereby mitigating the severe disabilities and premature death associated with Cockayne Syndrome.
Implementation Method 1
treating a patient's body fluid extracorporeally with an antibody or multiple antibodies to react and precipitate out targeted antigens of either death-associated protein 1 (DAP1) and/or mammalian target of rapamycin (mTOR) proteins
Implementation Method 2
High powered magnets are used to localize the magnetic beads to the side of the treatment chamber to enable cell lysate aspiration
Data Source
AI summary
Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mammalian target of rapamycin (mTOR) antigen or a death-associated protein 1 (DAP1) in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient.